Fujitsu Biosciences Licencses BioMedCAChe to GPC Biotech; New Version Due This Quarter

NEW YORK, Jan. 14 (GenomeWeb News) - Fujitsu America's BioSciences has recently signed a global licensing agreement for its BioMedCAChe suite of docking and molecular-modeling software with GPC Biotech.

GPC Biotech will implement the software in its Waltham, Mass.; and Martinsried/Munich, Germany, sites, Fujitsu said in early January. Michael McManus, vice president of the Fujitsu BioSciences group, did not provide the total number of researchers expected to use the software at GPC, but said that the desktop product will be used by the company's medicinal chemists, rather than its computational chemists.

McManus said that he has witnessed a trend over the last two years in which "the computational groups are realizing that they don't have the resources to really service all of the needs of the bench chemists." Therefore, he said, they're "starting to look for a reliable desktop software tool that can do a fair bit, but still has the ability to allow them to monitor or influence the content."

McManus told BioInform, a GenomeWeb News publication, that the company plans to release a new version of the software - expected some time in the first quarter - that will include more "high-performance" features for both the Windows and Mac platforms, and additional flexibility for modifications by computational chemistry groups.

This article originally appeared in  BioInform.